Protalix Biotherapeutics Inc. (PLX)

0.29
0.03 7.94
AMEX : Health Services
Prev Close 0.32
Open 0.33
Day Low/High 0.26 / 0.34
52 Wk Low/High 0.17 / 0.60
Volume 4.00M
Avg Volume 343.90K
Exchange AMEX
Shares Outstanding 148.38M
Market Cap 26.86M
EPS -0.20
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

IIROC Trading Resumption - PLX

IIROC Trading Resumption - PLX

VANCOUVER, Sept. 12, 2019 /CNW/ - Trading resumes in: Company: Point Loma Resources Ltd.

IIROC Trading Halt - PLX

IIROC Trading Halt - PLX

VANCOUVER, Sept. 11, 2019 /CNW/ - The following issues have been halted by IIROC: Company: Point Loma Resources Ltd.

IIROC Trading Resumption - PLX

IIROC Trading Resumption - PLX

VANCOUVER, Sept. 11, 2019 /CNW/ - Trading resumes in: Company: Point Loma Resources Ltd.

IIROC Trading Halt - PLX

IIROC Trading Halt - PLX

VANCOUVER, Sept. 10, 2019 /CNW/ - The following issues have been halted by IIROC: Company: Point Loma Resources Ltd.

Protalix BioTherapeutics Receives Listing Deficiency Letter From NYSE American

Protalix BioTherapeutics Receives Listing Deficiency Letter From NYSE American

CARMIEL, Israel, Aug. 30, 2019 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc.

Protalix BioTherapeutics Focuses On Evaluating And Pursuing Alternatives To Maximize Shareholder Value Through Refinancing & Strategic Partnerships

Protalix BioTherapeutics Focuses On Evaluating And Pursuing Alternatives To Maximize Shareholder Value Through Refinancing & Strategic Partnerships

CARMIEL, Israel, Aug. 22, 2019 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc.

Shlomo Yanai Resigns As Chairman Of The Board Of Protalix BioTherapeutics

Shlomo Yanai Resigns As Chairman Of The Board Of Protalix BioTherapeutics

CARMIEL, Israel, Aug. 13, 2019 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc.

Protalix BioTherapeutics Reports Second Quarter 2019 Results And Provides Corporate Update

Protalix BioTherapeutics Reports Second Quarter 2019 Results And Provides Corporate Update

CARMIEL, Israel, Aug. 08, 2019 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc.

Protalix BioTherapeutics To Hold Second Quarter 2019 Financial Results And Corporate Update Conference Call On August 8, 2019

Protalix BioTherapeutics To Hold Second Quarter 2019 Financial Results And Corporate Update Conference Call On August 8, 2019

CARMIEL, Israel, July 29, 2019 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc.

Protalix BioTherapeutics Appoints Eyal Rubin As Its New Senior Vice President And Chief Financial Officer

Protalix BioTherapeutics Appoints Eyal Rubin As Its New Senior Vice President And Chief Financial Officer

CARMIEL, Israel, July 29, 2019 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc.

Plexure Signs Deal With US Fast-food Chain White Castle

Plexure Signs Deal With US Fast-food Chain White Castle

AUCKLAND, New Zealand, July 21, 2019 /PRNewswire/ -- Plexure Group (NZX: PLX) has today signed a deal with United States' fast-food burger chain White Castle, adding to the momentum reflected in its recently-announced FY19 annual result.

Plexure Launches AI Driven Analytics Studio, Following McDonald's Investment

Plexure Launches AI Driven Analytics Studio, Following McDonald's Investment

AUCKLAND, New Zealand, June 27, 2019 /PRNewswire/ -- Hot off the heels of strong 2019 financials -- which included the ultimate vote of confidence from McDonald's, who purchased a 9.

First Week Of PLX May 2019 Options Trading

First Week Of PLX May 2019 Options Trading

Investors in Protalix BioTherapeutics Inc saw new options begin trading this week, for the May 2019 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 232 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Protalix BioTherapeutics' Pegunigalsidase Alfa Receives Fast Track Designation From The U.S. Food And Drug Administration

Protalix BioTherapeutics' Pegunigalsidase Alfa Receives Fast Track Designation From The U.S. Food And Drug Administration

Fast Track designation highlights high unmet medical need in the treatment of Fabry disease

Protalix BioTherapeutics To Participate In The 14th Annual WORLDSymposium™ 2018

Protalix BioTherapeutics To Participate In The 14th Annual WORLDSymposium™ 2018

Data to be presented in an oral presentation and two poster presentations

Protalix BioTherapeutics Announces Presentation To Be Made At The New Horizons In Fabry Disease Conference

Protalix BioTherapeutics Announces Presentation To Be Made At The New Horizons In Fabry Disease Conference

Oral Presentation of Long Term Results from the Phase I/II Open-Label Extension Trial of PRX-102 for Fabry Disease

TheStreet Quant Rating: E+ (Sell)